百奥赛图及其子品牌“百奥动物BioMice”将亮相于2023年11月1-5日在美国圣地亚哥举办的第38届癌症免疫治疗学会年会（SITC）。期间将展示16张海报，包括7张基因编辑动物模型海报和9张新药资产海报；并设立展台223。

欢迎在海报及展台与我们的团队见面，了解我们在临床前动物模型和服务（BioMice）及抗体新药研发方面的最新进展。无论您对我们货架型动物/细胞模型、药理药效服务、货架型新药资产还是全人抗体/TCR发现平台感兴趣，我们都期待与您洽谈合作，支持您的研发需求。

海报展示：

靶点人源化小鼠模型

Development of a preclinical CD98HC mouse model for therapeutic studies

海报编号: 13

展出时间: November 3rd, 2023

Generation and validation of humanized GARP/TGFB1 mice for testing novel anti-human GARP antibodies

海报编号: 18

展出时间: November 4th, 2023

Humanized CD200/CD200R mice as a tool for evaluating novel therapeutics

海报编号: 12

展出时间: November 4th, 2023

Humanized ICOS mice as a novel tool for predicting and monitoring T-cell-mediated immunotherapy response

海报编号: 11

展出时间: November 3rd, 2023

Humanized NKP46 mouse models for testing novel NK cell-based immunotherapies

海报编号: 17

展出时间: November 3rd, 2023

Preclinical CD3-based mouse models for evaluation of bi-specific T-cell engager antibodies

海报编号: 19

展出时间: November 3rd, 2023

靶免疫缺陷小鼠模型

A novel B2m-deficient immunodeficient model expressing human IL-15 for preclinical evaluation of T cell and NK cell-based therapies

海报编号: 16

展出时间: November 4th, 2023

双抗ADC药物资产

DM001: A novel bispecific ADC targeting TROP2 and EGFR with potent anti-tumor efficacy in PDX models

海报编号: 1152

展出时间: November 4th, 2023

Preclinical evaluation of fully human bispecific antibody-drug candidates targeting HER3 and the juxtamembrane region of MUC1

海报编号: 1165

展出时间: November 3rd, 2023

DM005, an EGFR х MET bispecific antibody-drug conjugate, showed robust anti-tumor activity in PDX models

海报编号: 1150

展出时间: November 4th, 2023

BSA01, a bispecific antibody-drug conjugate targeting EGFR and membrane-bound MUC-1-C, exhibits anti-tumor efficacy in vivo

海报编号: 1164

展出时间: November 4th, 2023

BCG022: A HER3×MET bispecific antibody-drug conjugate (BsADC) targeting key mechanisms of bypass resistance in multiple tumor types

海报编号: 1153

展出时间: November 3rd, 2023

A novel bispecific antibody-drug conjugate targeting PTK7 and TROP2, BCG033, demonstrates preclinical efficacy against triple-negative breast cancer xenografts

海报编号: 1163

展出时间: November 3rd, 2023

类TCR抗体新药资产

Identification of fully human TCR-mimic antibodies targeting the KRAS G12V/HLA complex generated in HLA-transgenic RenMabTM mice

海报编号: 1168

展出时间: November 4th, 2023

Preclinical application of a fully human TCR-mimic antibody developed to target NY-ESO-1/HLA-A02

海报编号: 356

展出时间: November 4th, 2023

全人单抗药物资产

Fc-competent fully human anti-TIGIT blocking monoclonal antibodies demonstrated potent anti-tumor efficacy in preclinical models

海报编号: 479

展出时间: November 3rd, 2023

----联系我们，了解更多项目信息：

1）抗体新药研发：BD-Licensing@biocytogen.com；

2）BioMice：info@bbctg.com.cn。